PetMed Express, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PETS research report →
Range $1.4 – $1.4
Price Chart
About the company
PetMed Express, Inc. , through its various subsidiaries, operates as a prominent pet pharmacy across the United States. The company provides a comprehensive range of both prescribed and over-the-counter animal medications, health-related items, and other essential supplies for canines, felines, and equines.
- CEO
- Jeffrey Allen Willard
- IPO
- 1999
- Employees
- 189
- HQ
- Delray Beach, FL, US
Get TickerSpark's AI analysis on PETS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.90M
- P/E
- -0.66
- PEG
- -0.01
- P/S
- 0.12
- P/B
- 1.06
- EV/EBITDA
- -0.39
- Div Yield
- 0.00%
- Gross Margin
- 23.36%
- Op Margin
- -17.98%
- Net Margin
- -16.97%
- ROE
- -107.10%
- ROIC
- -165.88%
Latest fiscal year · YoY change
- Revenue
- $179.02M-21.1%
- Gross Profit
- $40.83M-40.9%
- Op Income
- $-31,415,000
- Net Income
- $-57,286,000-813.5%
- EPS
- $-2.74-813.3%
- OCF Growth
- -701.8%
- FCF Growth
- -8256.7%
- 52W High
- $4.10
- 52W Low
- $0.85
- 50D MA
- $1.27
- 200D MA
- $1.95
- Beta
- 0.83
- RSI (14)
- 21
- Avg Volume
- 118.20K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
PetMed Express reported a smaller Q1 loss and continued expense discipline, while sales remained pressured by prescription softness and the company leaned harder into technology upgrades, partnerships, and asset monetization.· August 13, 2026
- Q1 net sales were $41 million, down 19.9% year over year, but management said sales have stabilized sequentially above $40 million for three straight quarters.
- Net loss narrowed sharply to $6.1 million, or $0.28 per diluted share, versus a $34.2 million loss a year ago, helped by lower operating expenses and no repeat goodwill impairment.
- Gross profit was $11.3 million, with gross margin of 27.6% versus 28.1% last year, while G&A fell 13.5% and advertising fell 30.2%.
- Customer acquisition improved: about 70,000 new customers were added and customer acquisition cost dropped to $60 from $71 a year ago.
- Management highlighted the Rural King white-label pharmacy launch and a $37 million sale-leaseback of headquarters/distribution assets as key strategic steps to grow and strengthen the balance sheet.
Net sales were $41 million versus $51.2 million last year, a 19.9% decline. Gross profit was $11.3 million versus $14.4 million last year, and gross margin was 27.6% versus 28.1%. General and administrative expense was $11.2 million, down 13.5%, and advertising expense was $4.2 million, down 30.2%. Net loss was $6.1 million, or $0.28 per diluted share, versus a net loss of $34.2 million, or $1.65 per diluted share, last year. Adjusted EBITDA loss was $3.4 million versus a loss of $2.7 million last year. As of June 30, 2026, cash and cash equivalents were $13.1 million and debt was zero. Management did not provide formal next-quarter or full-year financial guidance on the call.
Leslie C. G. Campbell framed the quarter as evidence that PetMed is building a more disciplined operating base, with a focus on shareholder value, cost control, customer retention, and new revenue streams. She emphasized technology modernization, including a new call center platform, fraud prevention, SAP ERP rollout, and faster freight service, as enabling better service and efficiency. Her tone was constructive but guarded, repeatedly stressing sustainable profitability and the board’s openness to strategic alternatives that could enhance value.
Doug Krulik focused on the quarter’s cost reductions and the mechanics behind the improved bottom line. He cited gross profit of $11.3 million, gross margin of 27.6%, G&A of $11.2 million, advertising of $4.2 million, and a net loss of $6.1 million, noting the comparison benefited from the absence of last year’s goodwill and trade name impairment charge. He also pointed to a $13.1 million cash balance, no debt, and no formal guidance issued.
There was no analyst Q&A in the transcript. The closest discussion points were management’s commentary on the unsolicited SilverCape proposal to buy the company for $3 per share and the ongoing CEO search. Management said the board had not reached a determination on the proposal and would not comment further unless additional disclosure was required, while the permanent CEO search remains a high priority.
The bull case from this call is that PetMed is showing signs of operational stabilization: sales have held above $40 million for three quarters, new customer acquisition is up, and CAC is down to $60. Management also pointed to Rural King as the first large-scale white-label pharmacy partnership and said more partners could follow, which could diversify acquisition beyond expensive traditional advertising.
The bear case is that revenue still fell 19.9% year over year, with prescription medication softness called out as the main drag, and adjusted EBITDA loss widened to $3.4 million. The company did not provide formal guidance, and the board is still considering an unsolicited acquisition proposal, which underscores strategic uncertainty. Cash was only $13.1 million at quarter-end, so execution on profitability, partnerships, and the planned sale-leaseback remains important.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 60.6%
- Shares Outstanding
- 22.23M
- Float Shares
- 13.47M
of shares held by institutions
51 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Renaissance Technologies LLC | 1.07M | ▼ 60.60K |
| Vanguard Group Inc | 963.76K | ▼ 293 |
| Vanguard Capital Management LLC | 827.40K | 0 |
| Blackrock, Inc. | 467.75K | ▼ 100.51K |
| Tudor Investment Corp Et Al | 251.60K | ▲ 170.20K |
| Umb Bank, N.A. | 235.00K | ▲ 175.00K |
| Steel Partners Holdings L.P. | 193.66K | 0 |
| Geode Capital Management, LLC | 175.66K | ▼ 28.41K |
| Ubs Group AG | 169.20K | ▲ 30.87K |
| State Street Corp | 138.27K | ▲ 33.10K |
| Bridgeway Capital Management, LLC | 133.54K | ▲ 12.49K |
| Federated Hermes, Inc. | 131.20K | ▼ 80.97K |
Held by 38 ETFs
Biggest fund positions in PETS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 27, 26 | KRULIK DOUGLAS | other | 3,246 |
| Oct 30, 26 | KRULIK DOUGLAS | other | 2,435 |
| Mar 9, 26 | KRULIK DOUGLAS | other | 2,965 |
| Sep 27, 25 | KRULIK DOUGLAS | other | 3,246 |
| Sep 28, 26 | Willard Jeffrey Allen | other | 250,000 |
| Sep 28, 26 | Willard Jeffrey Allen | other | 250,000 |
| Sep 28, 26 | Willard Jeffrey Allen | other | 0 |
| Sep 17, 26 | Elkeles Tamar | other | 49,923 |
| Sep 17, 26 | Elkeles Tamar | other | 0 |
| Aug 11, 26 | Campbell Leslie C.G. | other | 60,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PETS coverage
Recent articles, reports, and earnings notes.
Want a deeper read on PETS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
PetMed (PETS) Reports Q2 Loss, Lags Revenue Estimates
zacks.com · Nov 10
PetMed Express, Inc. (PETS) Q2 2027 Earnings Call Prepared Remarks Transcript
seekingalpha.com · Nov 10
PetMeds® Announces Second Quarter Financial Results
globenewswire.com · Nov 10
PetMeds Announces Strategic Partnership with Pet Supermarket to Expand Pharmacy Offering Across Retail and Digital Channels
globenewswire.com · Nov 9
PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026
globenewswire.com · Oct 27
PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 2
PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director
globenewswire.com · Sep 21
PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition
globenewswire.com · Sep 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
